Chemotherapy remains an important part of cancer treatment, but it can take a significant toll on the body. Nausea, vomiting, fatigue, digestive problems, mouth sores, and changes in blood counts can make an already difficult experience harder.
An intriguing area of research asks whether short-term fasting could help the body tolerate chemotherapy better. Recent clinical studies suggest it may reduce certain side effects in some patients. There is also early evidence that fasting could influence how tumors respond to treatment. However, this approach requires careful medical supervision.
One reason fasting has attracted attention involves a process called differential stress resistance. It sounds complicated, but the basic idea is fairly straightforward.
When nutrients become scarce, healthy cells can shift their priorities. Instead of emphasizing growth, they put more energy into maintenance and protection. This response may make normal cells more resistant to chemotherapy-related stress.
Cancer cells behave differently. Their abnormal growth signals can prevent them from making the same protective adjustment. Researchers believe this difference may leave cancer cells exposed while healthy cells become more resistant.
Fasting also changes the metabolic environment inside the body. Research has identified changes involving:
These changes may help explain why fasting is being studied alongside chemotherapy. However, the idea is more sophisticated than simply "starving cancer."
There is no single fasting protocol that has been proven best for every cancer patient. Studies have tested several approaches with different durations.
Short-term fasting commonly begins about 24 to 36 hours before chemotherapy. It may continue until approximately 24 hours after treatment. That creates a fasting window of roughly 48 to 72 hours.
Water is generally allowed throughout these protocols. Maintaining proper hydration is important during cancer treatment.
Researchers have also studied fasting-mimicking diets, often called FMDs. These are different from water-only fasting.
An FMD provides a small amount of carefully selected food. Some research protocols provide about 600 calories daily. Foods may include plant-based soups, crackers, broths, and herbal teas.
The intention is to produce some metabolic effects associated with fasting. Patients still receive a limited amount of nutrition.
Neither approach should be started simply by following instructions found online. Cancer treatment requires individualized nutritional decisions.
This is where the research becomes particularly interesting for patients. Several studies suggest fasting may reduce specific treatment-related symptoms.
A 2024 systematic review examined seven randomized controlled trials. Researchers found meaningful reductions in several problems among fasting patients, including:
The review also found fewer treatment delays related to side effects. Another 2024 review suggested fasting may help reduce unintended damage to healthy DNA. Some research has also found improvements in fatigue.
Some of the strongest clinical evidence comes from breast cancer research.
The multicenter randomized phase 2 DIRECT trial included 131 patients with early-stage breast cancer. Participants received chemotherapy before surgery.
One group followed a fasting-mimicking diet before and during chemotherapy. The other continued its usual diet.
Patients following the fasting-mimicking diet showed less chemotherapy-related DNA damage in immune cells. They were also more likely to experience complete or partial tumor shrinkage on imaging.
Researchers reported another notable finding. Patients following the diet were almost four times more likely to have 90 to 100 percent tumor-cell destruction at surgery.
A smaller randomized trial published in 2024 studied 44 breast cancer patients. These patients received chemotherapy before surgery across eight treatment cycles.
The fasting-mimicking group experienced lower rates of severe vomiting and dangerously low white blood cell counts. Researchers also reported better preservation of red blood cells.
Favorable changes occurred in IGF-1 and an inflammatory blood marker. Tumor response also favored the fasting-mimicking group.
One important development involves research beyond breast cancer.
At the 2026 American Society of Clinical Oncology Annual Meeting, researchers presented a pilot randomized ovarian cancer trial. The study included 36 women with advanced high-grade ovarian cancer.
Participants either followed their normal diet or completed short-term fasting. The fasting period lasted 36 hours before chemotherapy and 24 hours afterward. Water remained permitted.
The fasting group experienced reduced insulin levels. Insulin levels increased in the group eating normally.
Researchers also reported encouraging differences in tumor response. Nearly three in five fasting patients experienced a complete or near-complete response before surgery. The normal-diet group had a substantially lower response rate.
The fasting group also went roughly three years before cancer progression or recurrence. That compared with approximately two years for the control group.
These results certainly deserve attention. However, this was a small pilot study involving only 36 patients. We need larger multicenter trials before drawing conclusions about survival or recurrence.
Reducing side effects is only one part of this research. Scientists are also investigating whether fasting could make cancer cells more vulnerable to treatment.
Laboratory evidence provides biological reasons why this might occur. Reduced insulin and IGF-1 signaling may place additional metabolic stress on malignant cells.
Researchers are examining several possible mechanisms:
Human trials have provided some encouraging signals. The breast and ovarian cancer studies are particularly interesting. Still, these findings should not be interpreted as proof across all cancers.
This is an essential part of the conversation. Fasting may be reasonable for some patients and inappropriate for others.
Cancer itself can cause weight and muscle loss. Chemotherapy may also reduce appetite and make maintaining adequate nutrition difficult.
Fasting deserves particular caution in patients who:
Cancer cachexia is another major concern. This condition involves significant weight and muscle loss. Maintaining adequate calories and protein may be far more important than fasting for these patients.
The evidence available in 2026 is encouraging, but important questions remain unanswered.
A 2023 systematic review examined nine publications involving 379 patients. Several studies showed improved tolerability or reduced chemotherapy toxicity. However, much of the evidence was considered low to moderate quality.
Researchers also face another challenge. Studies have used different fasting schedules, diets, cancer populations, and chemotherapy regimens.
That makes broad recommendations difficult. We still need larger trials that examine:
This is why I believe personalized medicine is so important. We should not simply ask whether fasting "works."
Cancer treatment is rarely a situation where one strategy makes sense for everyone. The goal should be to support the whole patient while appropriately treating the cancer. Nutrition, metabolic health, conventional oncology, and supportive therapies can all be considered within that larger picture.
Fasting research gives us another potentially valuable area to explore. The 2026 evidence adds to that promise, but careful patient selection remains essential. The best approach is one built around the individual rather than the latest health trend.
If you or a loved one is undergoing cancer treatment, we can help you explore evidence-based integrative support. Your plan should account for your diagnosis, treatment, nutritional needs, laboratory findings, and overall health.
Stengler Center for Integrative Medicine
324 Encinitas Blvd
Encinitas, CA 92024
Phone: 760-274-2377
Toll-Free: 855-DOC-MARK
Email: clinic@markstengler.com
Office Hours:
Monday through Thursday: 8:30 a.m. to 4:00 p.m.
Friday: 8:30 a.m. to 2:00 p.m.
